Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.

Nektar has signed a definitive agreement to divest its Huntsville facility and associated reagent supply business to ...

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Alvotech and Advanz Pharma’s ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they ...

Fiona Barry is the Editor-in-Chief of GlobalData PharmSource’s editorial content. She previously worked as an investigative ...